Delivery Order SPE2DR25D1053-SPE2DR26FT295
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 17, 2025, for the supply of Tolvaptan 15 mg tablets in unit dose packages of 10 units. This is a firm fixed-price delivery order with a ceiling value of $5,100.87 and an ultimate completion date of July 18, 2025. The contract was awarded on a competitive basis without any set-aside designation. Performance will be executed from AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $22,092.55 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit dose packaging (10-count units). This firm fixed price contract, awarded on September 16, 2025, with an ultimate completion date of September 17, 2025, represents a non-set-aside competitive award. The pharmaceutical product will be delivered to the contractor's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $6,690.07 to AmerisourceBergen Drug Corp for Tolvaptan 15 mg tablets in unit dose packaging. This non-competitive delivery order, issued on August 5, 2025, with an ultimate completion date of August 6, 2025, represents a firm fixed price transaction for pharmaceutical supply. The contractor will perform this work at its corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded a delivery order valued at $33,218.27 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit dose packages of 10. This is a firm fixed price, competitively awarded contract with no set-aside designation, issued on June 16, 2025, with an ultimate completion date of June 17, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Tolvaptan 30 mg tablets in unit dose packaging of 10s. This contract is a non-set-aside, competitively awarded delivery order with firm fixed pricing, valued at $48,454.20, with a completion date of September 29, 2025. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $38,125.72 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 30 mg tablets in unit dose packaging of 10 tablets per package. This is a firm fixed price, non-set-aside contract with a completion date of May 28, 2025. The award was issued on May 27, 2025, with performance to be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Tolvaptan is a vasopressin receptor antagonist used primarily...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Tolvaptan 15 mg tablets in unit dose packaging on September 9, 2025. This competitively awarded, non-set-aside contract is valued at $15,578.98 and requires completion by September 10, 2025. The order will be fulfilled from AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, under a firm fixed-price arrangement typical of delivery orders against existing...
- The Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Tolvaptan 15 mg tablets in unit dose packaging (10-count). The contract carries a ceiling value of $181,808 under a firm fixed-price arrangement with a completion date of July 15, 2025. This non-competitive delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with the Defense Logistics Agency Troop...
- The Defense Logistics Agency awarded a delivery order valued at $15,233.64 to AmerisourceBergen Drug Corp for the supply of Tolvaptan 15 mg tablets in unit dose packaging of 10s. This non-set-aside contract was competitively awarded on August 13, 2025, with an ultimate completion date of August 14, 2025, and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The contract utilizes firm fixed price pricing and represents a child delivery order issued under a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of Tolvaptan 15 mg tablets, a medication, with a ceiling value of $32,564.52 and a completion date of May 21, 2025. The contract is a firm fixed-price arrangement with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a significant...
- SPE2DR25D1053Indefinite Delivery Contract
- SPE2DR25D1053-SPE2DR26FT295Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Tolvaptan 30 mg tablets in unit-dose packaging of 10 units, with a ceiling value of $18,283.30. The award, issued on October 24, 2025, utilizes firm fixed-price pricing with an ultimate completion date of October 27, 2025. This is a non-set-aside competitive award with performance at AmerisourceBergen's Conshohocken, Pennsylvania location, and the delivery order is structured as a child contract under a larger vehicle. This delivery order falls under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare systems. The parent contract enables AmerisourceBergen to supply a broad range of pharmaceutical products and medical supplies to support Defense Health Agency, U.S. Coast Guard, and other government healthcare systems. Tolvaptan is a vasopressin receptor antagonist used for treating certain fluid balance disorders, reflecting the pharmaceutical distributor's role in supplying specialized medications to federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $18.3k | 10/24/25 |